Market closed
Zymeworks/$ZYME
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Ticker
$ZYME
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
294
Website
Zymeworks Metrics
BasicAdvanced
$869M
Market cap
-
P/E ratio
-$1.52
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$869M
Beta
1.19
52-week high
$17.11
52-week low
$7.97
Average daily volume
529K
Financial strength
Current ratio
4.097
Quick ratio
3.824
Long term debt to equity
4.716
Total debt to equity
5.526
Management effectiveness
Return on assets (TTM)
-14.69%
Return on equity (TTM)
-28.73%
Valuation
Price to revenue (TTM)
15.194
Price to book
2.39
Price to tangible book (TTM)
2.52
Price to free cash flow (TTM)
-15.994
Growth
Revenue change (TTM)
-86.52%
Earnings per share change (TTM)
-150.18%
3-year revenue growth (CAGR)
40.37%
3-year earnings per share growth (CAGR)
-30.10%
What the Analysts think about Zymeworks
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.
Zymeworks Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Zymeworks Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Zymeworks News
AllArticlesVideos
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
GlobeNewsWire·3 weeks ago
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewsWire·3 weeks ago
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Zymeworks stock?
Zymeworks (ZYME) has a market cap of $869M as of December 14, 2024.
What is the P/E ratio for Zymeworks stock?
The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of December 14, 2024.
Does Zymeworks stock pay dividends?
No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Zymeworks dividend payment date?
Zymeworks (ZYME) stock does not pay dividends to its shareholders.
What is the beta indicator for Zymeworks?
Zymeworks (ZYME) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.